Lexington, MA – October 19, 2026 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines will participate in a panel discussion on “Expanding the Universe of Druggable Oncology Targets” at the Goldman Sachs’ Healthcare Private Company Conferenceat 2:00 PM EST on October 19, 2026 in New York, New York.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact
IR@trianabio.com
- Publication in Nature supports TRI-611’s potential to expand the arsenal of therapeutic options for ALK+ NSCLC patients, both as a single agent and in combination with other ALK TKI therapies
- TRI-611 administration results in degradation of ALK fusion proteins, including wild-type and ALK TKI-resistant mutated versions
- The Trial-in-Progress presentation at ESMO will provide an overview of the ongoing phase 1/2 study and underscore the clinical advancement of TRI-611
TRIANA Biomedicines, Inc. (TRIANA), a clinical-stage biopharmaceutical company focused on developing innovative molecular glue therapies for difficult-to-drug disease targets, leveraging its target-first and proximity-first molecular glue discovery platform, today announced the publication of a manuscript titled “TRI-611, a selective, brain-penetrant molecular glue degrader of ALK,” in the international peer-reviewed scientific journal, Nature. These preclinical results support the ongoing clinical development of TRI-611, which will be featured in a Trial-in-Progress poster presentation at European Society of Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
Tyrosine kinase inhibitors (TKIs) targeting Anaplastic Lymphoma Kinase (ALK) have made noteworthy contributions to the treatment of ALK fusion-positive non-small cell lung cancer (ALK+ NSCLC), but are limited by tolerability issues and resistance mutations. TRI-611 represents the first example of a clinical-stage molecular glue degrader targeting an oncogenic gene fusion and has the potential to expand the arsenal of therapeutic options for ALK+ NSCLC patients.
TRI-611 is an innovative product candidate discovered through TRIANA’s proximity-first approach to finding molecular glues to compelling disease targets. As a molecular glue degrader, TRI-611 promotes the proximity of the ALK kinase domain and the E3 Ligase Cereblon via a unique binding site distal from the kinase active site. Published data support the potency and selectivity of TRI-611 in targeting ALK oncogenic gene fusions. Administration of TRI-611 induces degradation of ALK fusion proteins, including wild-type and ALK TKI-resistant mutated versions, leading to tumor regression in preclinical cell line-derived and patient-derived subcutaneous and intracranial tumor models of ALK+ NSCLC. TRI-611’s novel mechanism of action may also offer therapeutic potential in combination with ALK TKI, resulting in synergistic and durable tumor regressions.
“This publication provides important validation of the scientific rationale supporting TRI-611 and adds to the growing body of preclinical evidence demonstrating the potential of our molecular glue platform,” said Dr. Vito Palombella, Chief Scientific Officer of TRIANA.
“We are excited to showcase our scientific leadership in the molecular glue field. Our goal is to build on this body of work and ultimately deliver TRI-611 as a meaningful new option for ALK fusion positive NSCLC patients both in early and later lines of treatment,” said Dr. Patrick Trojer, President and CEO of TRIANA. “Due to its new mechanism of action, TRI-611 may constitute a new product class and allow for combination strategies to further increase therapeutic options for patients.”
The ongoing Phase 1/2 study will be featured in a Trial-in-Progress poster at ESMO, further detailing the program’s clinical development strategy.
Poster presentation
- Title: TRI-611-101: A Phase 1/2 Trial of TRI-611 in ALK Fusion Positive Non-small Cell Lung Cancer (NSCLC) Patients
- Presentation Number: 2872 eTIP
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private, clinical-stage biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
To learn more about the clinical program of TRI-611 visit clinicaltrials.gov (NCT07491497).
Contact: IR@trianabio.com
Lexington, MA – September 2, 2026 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that management will participate in the following upcoming investor conferences:
Cantor Global Healthcare Conference
Participant: Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines
Location: New York, New York
Date: September 9, 2026
Goldman Sachs Life Science Symposium
Participant: Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines
Location: New York, New York
Date: September 15, 2026
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact – IR@trianabio.com
- COO appointment strengthens the leadership team in support of long-term growth and continued advancement of molecular glue degrader pipeline
- Addition of Drs. Maria Koehler and David Tuveson strengthens Scientific Advisory Board
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the appointment of Dr. Mohan Bala as Chief Operating Officer (COO). Additionally, Drs. Maria Koehler and David Tuveson join the Company’s growing Scientific Advisory Board (SAB).
Mohan Bala, PhD, brings more than 30 years of industry experience in program leadership, program development, market access, product strategy, and business development to TRIANA. His expertise spans the full development continuum, from early to late-stage programs, across both small biotech and large pharmaceutical organizations. He was closely involved in the launch of seven successful oncology products globally. Prior to joining TRIANA, he served as Chief Development Officer at Mersana Therapeutics, where he played a key role in business development efforts that culminated in the company’s acquisition by Day One Biopharmaceuticals. Before that, he was Chief Operating Officer at Constellation Pharmaceuticals, where he led multiple development functions, while also contributing significantly to the business activities that led to the company’s acquisition by MorphoSys. Earlier in his career, Dr. Bala held roles of increasing responsibility at TESARO, Sanofi, GlaxoSmithKline, Centocor, and Research Triangle Institute. He holds a PhD in Management Science from the University of Chicago.
“Mohan’s drug development prowess and his thoughtful approach to strategy, product positioning and market access makes him a strong addition to TRIANA’s leadership team as we advance our molecular glue degrader pipeline,” said Dr. Patrick Trojer, President and CEO of TRIANA. “We continue to push the boundaries of what is possible with molecular glue degrader therapies, and we look forward to collaborating closely with our new SAB members, Maria and David. Their perspective will be invaluable as we shape the future of our pipeline and aim to deliver meaningful outcomes for the patients we serve.”
“I’m excited to join TRIANA at this stage of its development. I was attracted by the Company’s molecular glue technology, the experience and vision of the leadership team, and the opportunity to advance a pipeline focused on patients with significant unmet needs,” said Dr. Mohan Bala. “I am particularly encouraged by the potential of TRI-611 for ALK+ NSCLC and look forward to working with the team as TRIANA continues to advance more of its pipeline programs into the clinic.”
Maria Koehler, MD, PhD, is a board-certified hematologist-oncologist with an academic bone marrow transplant career and more than 20 years of experience in oncology drug development across leading global pharmaceutical and biotechnology companies. She currently is a Partner at Omega Funds, as well as a senior advisor to Viking Global Investors LP. Dr. Koehler serves as an independent director on the boards of Remix Therapeutics, Orum Therapeutics and Abdera Therapeutics. Previously, Dr. Koehler was Chief Medical Officer and Executive Vice President at Repare Therapeutics, Chief Medical Officer at Bicycle Therapeutics and Vice President of Strategy & Innovation at Pfizer Oncology. Her earlier career included senior leadership roles at AstraZeneca, GSK, and Pfizer. She earned her MD and PhD from Silesian School of Medicine in Poland.
David Tuveson, MD, PhD, FAACR is an internationally recognized physician-scientist and leader in the field of translational oncology. He serves as Director of the Cold Spring Harbor Laboratory Cancer Center and is the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory. He also serves as Chief Scientist of the Lustgarten Foundation for Pancreatic Cancer Research. Prior to joining Cold Spring Harbor Laboratory, Dr. Tuveson held faculty positions at the University of Pennsylvania and the University of Cambridge. He is a past President of the American Association for Cancer Research and has been elected to the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Tuveson earned his MD and PhD from the Johns Hopkins University School of Medicine and completed his clinical and fellowship training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, respectively.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced one oral and three poster presentations regarding the Company’s clinical asset, TRI-611, as well as its preclinical asset Cyclin E1 (CCNE1) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
TRIANA will present data highlighting the first-in-class clinical stage compound TRI-611 as a selective, brain-penetrant molecular glue degrader for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). In pre-clinical ALK+ NSCLC tumor models, TRI-611 promotes the degradation of tyrosine kinase inhibitor (TKI)-sensitive and -resistant ALK fusion proteins and leads to regression of both ALK TKI-refractory subcutaneous and intracranial tumors. TRI-611 demonstrates combinability with ALK TKIs in pre-clinical tumor models, potentially opening additional therapeutic avenues for patients with ALK+ NSCLC.
“We are pleased to provide further preclinical data highlighting the breadth of our molecular glue degrader therapeutics portfolio,” said Dr. Patrick Trojer, President and CEO of TRIANA. “By binding at a site distal to the TKI domain binding site, TRI-611 tethers the E3 ligase complex cereblon to ALK fusion proteins, promoting their destruction by engaging the cell’s own degradation machinery. This mechanism renders potent tumor regression activity, irrespective of mutations in the TKI binding domain.”
Oral Presentation Details:
Title: TRI-611, a potent, selective, CNS-penetrant ALK molecular glue degrader for the treatment of ALK-fusion protein positive non-small cell lung cancer
Abstract Number: ND07
Date and Time: Sunday, April 19, 2026, 3:45 p.m. – 4:00 p.m. PT
Session Category: New Drugs on the Horizon: Part 2
Session: DDT02
Location: Ballroom 20 CD – Upper Level – Convention Center
Poster Presentation Details:
Title: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors
Abstract Number: 5787 / 14
Date and Time: Tuesday, April 21, 2026, 2:00 p.m. – 5:00 p.m. PT
Session Category: Proximity-Induced Drug Discovery 2
Session: T09.04
Location: Poster Section 15
Title: TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases
Abstract Number: 4618 / 28
Date and Time: Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT
Session Category: Proximity-Induced Drug Discovery 1
Session: ET09.03
Location: Poster Section 18
Title: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers
Abstract Number: 5789 / 16
Date and Time: Tuesday, April 21, 2026, 2:00 p.m. – 5:00 p.m. PT
Session Category: Proximity-Induced Drug Discovery 2
Session: ET09.04
Location: Poster Section 15
About TRI-611
TRI-611 is a novel oral, small-molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK+ NSCLC. TRI-611 is a potent, brain-penetrant molecular glue degrader that brings ALK fusion proteins and the E3 ligase enzyme cereblon together through a unique binding mechanism that works independently of the ALK kinase active site and harnesses the body’s innate protein-degradation machinery to selectively eliminate the ALK fusion protein. TRI-611 is designed to overcome the limitations observed with currently available ALK inhibitors.
About CCNE1
CCNE1 (cyclin E1) is a key disease driver in CCNE1-amplified tumors and in a subset of HR+/HER2- breast cancers. As a critical regulator of the cell cycle, CCNE1 protein levels are tightly regulated to maintain control of cell growth in normal cells, while elevation of CCNE1 protein levels can lead to aberrant cell growth in cancer. CCNE1 has been difficult to drug with traditional approaches. Our novel oral, small-molecule molecular glue degraders of CCNE1 offer a unique approach to targeting this key cancer driver by harnessing the cell’s protein degradation machinery to substantially decrease excess CCNE1 and halt growth of CCNE1-dependent tumor cells.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com
- There is an urgent need for innovative therapeutic options that impact disease progression after failure with standard of care, ALK tyrosine kinase inhibitor therapies
- TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader targeting ALK fusion proteins
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TRI-611, an investigational molecular glue degrader therapy for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).
Fast Track designation is a U.S. Food and Drug Administration (FDA) program intended to accelerate the development and review of new drugs that have the potential to treat serious conditions and address urgent unmet medical needs.
“This Fast Track designation underscores the potential of TRI-611 to address the significant unmet need for patients with ALK+ NSCLC who have been previously treated with two or more ALK tyrosine kinase inhibitors,” said Dr. Patrick Trojer, President and CEO of TRIANA. “TRI-611 was designed as an innovative therapeutic approach to target ALK fusion proteins. We look forward to working closely with the FDA to potentially bring TRI-611 forward to the lung cancer patient community.”
Earlier in March 2026, TRIANA announced that the first patient had been treated with TRI-611 in a Phase 1/2 clinical study. The Phase 1/2 trial is a global, first-in-human, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611 in patients with ALK+ NSCLC. The Phase 1 portion will consist of a dose escalation design, enrolling ALK+ NSCLC patients, who have been previously treated with standard of care ALK tyrosine kinase therapies. The Phase 2 portion will further evaluate and characterize the efficacy and safety of TRI-611 across different patient cohorts. For more information, visit ClinicalTrials.gov (NCT07491497).
About TRI-611
TRI-611 is a novel oral, small-molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK+ NSCLC. TRI-611 is a potent, brain-penetrant molecular glue degrader that brings ALK fusion proteins and the E3 ligase enzyme cereblon together through a unique binding mechanism that works independently of the ALK kinase active site and harnesses the body’s innate protein-degradation machinery to selectively eliminate the ALK fusion protein. TRI-611 is designed to overcome the limitations observed with currently available ALK inhibitors.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com
- TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s innate protein-degradation machinery to target ALK fusion proteins for destruction
- Initiation of clinical trial marks strategic milestone for TRIANA’s novel molecular glue degrader platform
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating TRI-611, a novel ALK-fusion molecular glue degrader, in patients with anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer cases. ALK+ NSCLC represents an important subset of lung cancer, characterized by a dependence on ALK fusion proteins for its growth and survival. Despite therapeutic advances with ALK tyrosine kinase inhibitors (TKI), resistance to TKI-based therapies and limited combination therapy options remain major clinical challenges for these younger, non-smoking patients, underscoring the profound and long-lasting impact of this disease. Addressing this persistent unmet need represents a significant opportunity to elevate the standard of care and meaningfully improve outcomes for people living with ALK+ NSCLC.
The Phase 1/2 clinical trial is a global, first-in-human, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611 in patients with ALK+ NSCLC. The Phase 1 portion will consist of a dose escalation design, enrolling ALK+ NSCLC patients, who have been previously treated with standard of care ALK TKI therapies. The Phase 2 portion will further evaluate and characterize the efficacy and safety of TRI-611 across different patient cohorts.
“We are excited to have TRI-611 in the clinic and to advance this new potential therapy for people living with lung cancer,” said Dr. Caroline Germa, Chief Medical Officer of TRIANA. “Despite progress in treatments, many patients continue to face limited options. This study represents an important step in our mission to develop innovative therapies that may ultimately improve outcomes for ALK+ NSCLC patients and their families.”
“Dosing of the first patient with TRI-611 marks an important milestone for TRIANA and for the ALK+ NSCLC patient community,” said Dr. Patrick Trojer, President and CEO of TRIANA. “This study reflects our commitment to treating diseases in entirely new ways by applying our molecular glue technology to highly relevant cancer targets. We are excited to advance TRI-611 and bring its potential impact one step closer to patients.”
About TRI-611
TRI-611 is a novel oral, small molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK+ NSCLC. TRI-611 is a highly selective, potent, brain-penetrant, molecular glue degrader that brings ALK and the E3 ligase cereblon together through a unique binding mechanism that works independently of the kinase active site. TRI-611 harnesses the body’s innate protein-degradation machinery to selectively eliminate the ALK fusion protein and is designed to overcome the limitations observed with currently available ALK inhibitors.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced a research collaboration with Johnson & Johnson* to advance the discovery of important molecular glue targets in oncology.
The collaboration aims to advance next-generation molecular glue degraders by applying TRIANA’s proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered undruggable. Molecular glues represent a potentially transformative modality that enables selective elimination of disease-driving proteins, opening the door to more accessible, durable, and differentiated therapeutics for patients.
“This collaboration agreement underscores TRIANA’s unique ability to discover promising therapeutics against hard-to-drug targets,” said Dr. Patrick Trojer, President and CEO of TRIANA. “We believe our molecular-glue discovery engine represents an important and emerging drug modality—one with the potential to bring meaningful benefits to cancer patients. The strategic partnership brings together unique capabilities from both companies in the pursuit of successfully identifying cancer targeted molecular glue degraders.”
*Legal entity: Janssen Pharmaceutica NV
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com
- Financing co-led by new investors, Ascenta Capital and Bessemer Venture Partners
- Additional new investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures, along with continued support from existing investors
- Funding will support the advancement of lead asset, TRI-611, an ALK-targeted molecular glue degrader, to clinical proof of concept, for ALK+ NSCLC patients and accelerate maturation of multiple pipeline programs
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its oversubscribed $120 million Series B financing round.
The Series B financing was co-led by Ascenta Capital and Bessemer Venture Partners. New investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. TRIANA received continued support from existing founding investors RA Capital Management and Atlas Venture, along with Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital (a Citadel company). In association with the Series B financing, Lorence Kim, M.D., from Ascenta Capital, and Andrew Hedin, of Bessemer Venture Partners, will join TRIANA’s Board of Directors.
The proceeds from the financing will support development of lead product candidate TRI-611, an anaplastic lymphoma kinase–positive (ALK) targeted molecular glue degrader, to clinical proof of concept in ALK+ non-small cell lung cancer (NSCLC), selection of a second product candidate in 2026, and the advancement of TRIANA’s product pipeline beyond TRI-611.
While advances in ALK tyrosine kinase inhibitor therapies have markedly improved outcomes for patients with ALK+ NSCLC, acquired resistance and tolerability issues remain key challenges in this predominantly younger lung cancer subpopulation. Addressing this need presents a significant opportunity to advance the standard of care and improve the lives of patients living with ALK+ NSCLC.
“Successful closing of our Series B fundraising represents a major milestone in TRIANA’s mission to innovate therapies for difficult to treat cancers,” said Dr. Patrick Trojer, President and CEO of TRIANA. “We are pleased to have the strong backing of world-class investors and thank both our new and existing partners for their commitment to advancing our mission. We look forward to the clinical development of TRI-611 for lung cancer patients.”
“We’ve long viewed molecular glues as one of the most promising frontiers in targeted protein degradation,” said Andrew Hedin, Partner at Bessemer Venture Partners. “We’ve followed TRIANA closely as their world-class team has built a leading discovery engine to unlock this next-generation modality and deliver new therapies to patients. Their rapid execution and lead ALK+ non-small cell lung cancer program designed to overcome resistance seen with current treatments reflect the kind of bold, science-driven innovation that can transform patient outcomes.”
“We are impressed by TRIANA’s platform, with its target-first approach to rational molecular-glue design, and TRI-611, that selectively degrades ALK variants with a compelling pharmacologic profile,” said Dr. Lorence Kim, Managing Partner and Co-Founder of Ascenta Capital. “At Ascenta, we are drawn to platforms that unite deep mechanistic insight with clear clinical potential, and we look forward to supporting TRIANA as it grows to support a full clinical development effort to bring medicines closer to patients.”
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact: IR@trianabio.com